Free Newsletter
ALSO NOTED: GSK suing Abbott over HIV-drug price; Harvard genius joins MIT-Novartis effort;
> GlaxoSmithKline is joining a lawsuit against Abbott Laboratories over the jacked-up price of Norvir, and anti-HIV drug. Report
> A top Harvard chemist will join the MIT-Novartis Center for Continuous Manufacturing, a joint effort of the university and the Big Pharma company to develop new ways of making drugs. Report
> The FDA approved new labeling for the Bristol-Myers Squibb leukemia drug Sprycel; patients can now start on a lower dose of the drug, to help avert side effects. Report
> Indian pharma Wockhardt is considering a spin-off of its R&D operations, in the wake of similar moves by competitors. Report
> The FDA: Caught between a rock and a hard place. Report
And Finally... Athletes given placebo on competition day get a performance boost. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: